Antineoplastic drugs as etoposide (ETO) are widely utilized in leukemia cancer. Patient with leukemia cancer has a relative infection with pneumonia treated by fluoroquinolones as moxifloxacin HCL (MOX). Because opioid analgesic as nalbuphine HCL (NAL) does not have a ceiling dose, it is used to manage the distasteful sensory in leukemia cancer. Green chemistry advances innovative design to keep a healthy environment. Consequently, innovatory green processes for synchronous spectrofluorimetric quantification of a ternary mixture of antineoplastic, fluoroquinolone, and opioid analgesic drugs. The present study provides two eco-friendly synchronous fluorimetric processes (conventional and first derivative), conventional for MOX and the first derivative for ETO and NAL quantification. Conventional synchronous fluorimetric of MOX was monitored at 371 nm, while the first derivative synchronous fluorimetric of ETO and NAL was measured at 257 and 273 nm, respectively, in ethanol. The synchronous fluorescence was scanned at  λ of 60 nm for both processes. Environmentally friendly solvent as ethanol has a major role in the sensitivity, reproducibility, and quantitation of innovative processes. The outcomes of these designed environmentally friendly processes, a linear correlation was described in the ranges of 0.04-0.40, 0.1-1.0, and 0.5-5.0 g/mL for MOX, ETO, and NAL, respectively. Accordingly, several pharmaceutical dosages were achieved within the range simply and precisely. Additionally, synchronous assessment of ETO, MOX, and NAL in the biological fluid was attained by facile protein precipitation technique. These innovatory green processes were evaluated as accurate and precise processes regarding ICH roles. Greener innovative synchronous fluorimetric processes were corroborated by applying the National Environmental Methods Index, Analytical Eco-scale, and Green Analytical Procedure Index, which provides a novelty of the current study.

Two facile, green, and highly sensitive spectrofluorimetric approaches were conducted to simultaneous estimation the antineoplastic drug; etoposide (ETO), a fluoroquinolone antibiotic; moxifloxacin HCL (MOX) and opioid analgesic; nalbuphine HCL (NAL) in commercial formulations and spiked human urine. The first approach relies simply on estimation of MOX at 371 nm by synchronous fluorimetric technique. The second approach depends on applying the first derivative synchronous fluorimetric technique for simultaneous estimation of ETO and NAL at 257 and 273 nm, respectively. The developed methods are more convenient for routine quality control laboratory and therapeutic drug monitoring instead of the time-consuming and sophisticated reported techniques.

1- Full validation data of ETO at 257 nm.

2- Full validation data of MOX at 371 nm.

3- Full validation data of NAL at 273 nm.